Hippocratic AI has raised $141 million in a Series B funding round led by Kleiner Perkins, elevating its valuation to $1.64 billion and cementing its status as a healthcare AI unicorn. This funding brings the company’s total capital to $278 million, with contributions from major investors like a16z, NVIDIA, and General Catalyst. The company’s innovative AI Agent App Store enables clinicians to co-develop AI agents for various tasks, such as patient education and chronic care management, while earning revenue. Hippocratic AI’s Polaris 2.0 model has reached safety parity with human clinicians, a milestone that supports its focus on non-diagnostic applications like medication onboarding and patient wellness coaching. Key clients and development partners, including Cincinnati Children’s and OhioHealth, validate the company’s commitment to safety and clinical standards.
In just nine months since its Series A, Hippocratic AI has achieved rapid growth, securing partnerships with 23 healthcare organizations and completing over 200,000 patient interactions with high satisfaction ratings. Its proprietary Polaris architecture, scaled to 3.7 trillion parameters, has been instrumental in delivering reliable and safe AI solutions. With fresh funding, the company plans to expand internationally into Europe, the Middle East, Africa, Southeast Asia, and Latin America while also entering pharmaceutical and insurance sectors. CEO Munjal Shah emphasizes the role of AI agents in addressing healthcare staffing shortages by enhancing accessibility and operational efficiency. Hippocratic AI’s mission reflects a broader vision of creating an “abundance of healthcare” to meet increasing global care demands.
Read the full article here